Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Predicting Carfilzomib-Related Cardiovascular Adverse Events in Myeloma

July 2, 2019
By Leah Lawrence
Article

Researchers conducted a study to define risk factors for cardiovascular adverse events in patients with multiple myeloma who were taking proteasome inhibitors.

Cardiac adverse events occurred commonly among patients with multiple myeloma receiving carfilzomib, with more than half of patients experiencing an event, according to a new study published in the Journal of Clinical Oncology.

“The key finding was that natriuretic peptides, including brain natriuretic peptide [BNP] and N-terminal proBNP, are predictive biomarkers for patients at risk for cardiovascular events,” said Robert F. Cornell, MS, MD, of Vanderbilt University Medical Center, in an interview with Cancer Network. “Patients with elevated natriuretic peptides prior to carfilzomib administration or who experience increases in natriuretic peptides during treatment, particularly during the first cycle, are at highest risk for cardiovascular events.”

Specifically, patients receiving carfilzomib-based therapy with baseline elevated BNP greater than 100 pg/nL or N-terminal proBNP greater than 125 pg/mL had more than 10 times the risk for cardiovascular adverse events (odds ratio [OR], 10.8; P < .001). In addition, elevated natriuretic peptides that occurred mid–first cycle of treatment with carfilzomib were associated with significantly increased risk for cardiovascular adverse events (OR, 36.0; P < .001).

Cornell recommended checking this simple blood test on day 1 and 15 of each chemotherapy cycle for at least the first several cycles of treatment.

The study included 95 patients with relapsed myeloma initiating treatment with proteasome inhibitors carfilzomib (n = 65) or bortezomib (n = 30). The median follow-up was 25 months.

During the study, 64 cardiovascular adverse events occurred; 55% were grade 3 or worse. Significantly more cardiovascular adverse events occurred in patients receiving carfilzomib compared with bortezomib (51% vs 17%; P = .002). The median time to first cardiovascular adverse event was 31 days, and the majority (86%) occurred within the first 3 months.

Cardiovascular adverse events were associated with worse progression-free survival and overall survival, according to the study. Proteasome inhibitor therapy was safely resumed in 89% of patients, with 41% requiring chemotherapy modifications.

“While specific management changes are not recommended based on natriuretic peptides alone, patients with an elevation in BNP or N-terminal proBNP should be monitored closely during their treatment and cardiovascular health optimized,” Cornell said. “Patients with multiple cardiovascular risk factors, particularly those with a history of cardiovascular adverse events and/or elevated baseline natriuretic peptides, should be referred for a comprehensive cardiac evaluation.”

Commenting on the study, Yoshiaki Abe, PhD, of Kameda Medical Center in Japan, called the results important because there are no established predictors for severe cardiovascular adverse events.

“Cornell et al evaluated this crucially important clinical problem using a prospective study design and found that natriuretic peptides were predictive. This finding may harmonize with recent reports from us and others; carfilzomib induces diastolic dysfunction in a mouse model promptly after the drug administration and the presence and severity of baseline left ventricular diastolic dysfunction were associated with the occurrence of severe cardiovascular adverse events in real-world myeloma patients receiving carfilzomib,” Abe said. “The association between the levels of serum natriuretic peptide and diastolic function has been demonstrated in many populations and we recently confirmed this association in myeloma patients.”

Based on this, the results in this study seem reasonable and should be validated in the context of the detailed changes in cardiac function, including diastolic function using much larger cohorts.

“Based on my clinical experiences, I believe that carfilzomib can be used safely even in patients with higher natriuretic peptide levels or other cardiovascular risk factors if they are closely monitored,” Abe told Cancer Network. “I expect these recent reports regarding carfilzomib-associated cardiovascular adverse events will be of help to many clinicians for identifying patients who require such close management.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 12th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
September 12th 2025
Podcast

Data from a propensity-matched analysis showed that GLP-1 receptor agonists conferred benefits even among patients with type 2 diabetes.

GLP-1 Agonists Show Therapeutic Benefits in Polycythemia Vera Population

Ryan Scott
September 12th 2025
Article

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
September 12th 2025
Podcast

Reprogramming the Neuroblastoma Tumor Immune Microenvironment to Enhance GPC2 CAR T-cells

Reprogramming the Neuroblastoma Tumor Immune Microenvironment to Enhance GPC2 CAR T-cells

American Society for Transplantation and Cellular Therapy
September 12th 2025
Article

The overall pain experience among adult and pediatric patients with severe sickle cell disease significantly improved after exa-cel infusion.

Exa-cel Exhibits Meaningful HRQoL Benefit in Severe Sickle Cell Disease

Roman Fabbricatore
September 12th 2025
Article
Related Content

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 12th 2025
Article

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
September 12th 2025
Podcast

Data from a propensity-matched analysis showed that GLP-1 receptor agonists conferred benefits even among patients with type 2 diabetes.

GLP-1 Agonists Show Therapeutic Benefits in Polycythemia Vera Population

Ryan Scott
September 12th 2025
Article

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
September 12th 2025
Podcast

Reprogramming the Neuroblastoma Tumor Immune Microenvironment to Enhance GPC2 CAR T-cells

Reprogramming the Neuroblastoma Tumor Immune Microenvironment to Enhance GPC2 CAR T-cells

American Society for Transplantation and Cellular Therapy
September 12th 2025
Article

The overall pain experience among adult and pediatric patients with severe sickle cell disease significantly improved after exa-cel infusion.

Exa-cel Exhibits Meaningful HRQoL Benefit in Severe Sickle Cell Disease

Roman Fabbricatore
September 12th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.